Literature DB >> 35118176

Evaluating Human Natural Killer Cells Antibody-dependent Cellular Cytotoxicity (ADCC) Using Plate-bound Anti-CD16 Antibodies.

Weiru Liu1.   

Abstract

Natural killer (NK) cells are large granular lymphocytes that keep in check the health of neighboring cells through a large array of intrinsically expressed germline-coded receptors. Most importantly, CD16 is a low affinity Fc receptor for IgG that mediates the antibody-dependent cellular cytotoxicity (ADCC) of NK cells, bridging the innate and adaptive immunities. There has been a significant interest in genetically engineering NK cells to enhance its ADCC, with the ultimate goal to produce off-the-shelf NK cell therapy products that can be combined with target-specific monoclonal antibodies to improve clinical outcomes. Previous protocols of ADCC assays use complex cell-based antigen-antibody models, which are both costly and time-consuming. This current protocol is devoid of target cells and uses plate-bound immobilized anti-CD16 antibodies as the trigger. It greatly shortens the experimental time, while faithfully evaluating NK cells ADCC. Graphic abstract: Workflow of stimulating NK cells via CD16 by plate-bound anti-CD16 mAb.
Copyright © 2022 The Authors; exclusive licensee Bio-protocol LLC.

Entities:  

Keywords:  ADCC; CD16; Fc receptor; Human NK cell; Plate-bound assay

Year:  2022        PMID: 35118176      PMCID: PMC8769751          DOI: 10.21769/BioProtoc.4285

Source DB:  PubMed          Journal:  Bio Protoc        ISSN: 2331-8325


  7 in total

Review 1.  Innate or adaptive immunity? The example of natural killer cells.

Authors:  Eric Vivier; David H Raulet; Alessandro Moretta; Michael A Caligiuri; Laurence Zitvogel; Lewis L Lanier; Wayne M Yokoyama; Sophie Ugolini
Journal:  Science       Date:  2011-01-07       Impact factor: 47.728

2.  Targeting CD137 enhances the efficacy of cetuximab.

Authors:  Holbrook E Kohrt; A Dimitrios Colevas; Roch Houot; Kipp Weiskopf; Matthew J Goldstein; Peder Lund; Antonia Mueller; Idit Sagiv-Barfi; Aurelien Marabelle; Ruth Lira; Emily Troutner; Lori Richards; Amanda Rajapaska; Jonathan Hebb; Cariad Chester; Erin Waller; Anton Ostashko; Wen-Kai Weng; Lieping Chen; Debra Czerwinski; Yang-Xin Fu; John Sunwoo; Ronald Levy
Journal:  J Clin Invest       Date:  2014-05-16       Impact factor: 14.808

3.  Natural Killer Cells Generated From Human Induced Pluripotent Stem Cells Mature to CD56brightCD16+NKp80+/- In-Vitro and Express KIR2DL2/DL3 and KIR3DL1.

Authors:  Johanna Euchner; Jasmin Sprissler; Toni Cathomen; Daniel Fürst; Hubert Schrezenmeier; Klaus-Michael Debatin; Klaus Schwarz; Kerstin Felgentreff
Journal:  Front Immunol       Date:  2021-05-04       Impact factor: 7.561

Review 4.  Clinical cancer therapy by NK cells via antibody-dependent cell-mediated cytotoxicity.

Authors:  Kory L Alderson; Paul M Sondel
Journal:  J Biomed Biotechnol       Date:  2011-05-24

Review 5.  Chimeric antigen receptor natural killer (CAR-NK) cell design and engineering for cancer therapy.

Authors:  Ying Gong; Roel G J Klein Wolterink; Jianxiang Wang; Gerard M J Bos; Wilfred T V Germeraad
Journal:  J Hematol Oncol       Date:  2021-05-01       Impact factor: 17.388

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.